These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17768668)

  • 61. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
    Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
    Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of rehabilitation in Hurler's syndrome.
    Mishra SR; Shastri M; Ramesh J
    J Back Musculoskelet Rehabil; 2017; 30(3):635-639. PubMed ID: 27911282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.
    Sato Y; Fujiwara M; Kobayashi H; Yoshitake M; Hashimoto K; Oto Y; Ida H
    Mol Genet Metab Rep; 2015 Dec; 5():94-97. PubMed ID: 28649551
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
    Soutar RL; Mercer J; Wraith JE
    J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hematopoietic cell transplantation for severe MPS I in the first six months of life: The heart of the matter.
    Braunlin E; Miettunen K; Lund T; Luquette M; Orchard P
    Mol Genet Metab; 2019 Feb; 126(2):117-120. PubMed ID: 30503158
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
    Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
    Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
    [TBL] [Abstract][Full Text] [Related]  

  • 67. alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype.
    Scott HS; Litjens T; Nelson PV; Brooks DA; Hopwood JJ; Morris CP
    Hum Mutat; 1992; 1(4):333-9. PubMed ID: 1301941
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
    Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
    Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.
    Braunlin E; Orchard PJ; Whitley CB; Schroeder L; Reed RC; Manivel JC
    Cardiovasc Pathol; 2014; 23(3):145-51. PubMed ID: 24508139
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome.
    Conway J; Dyack S; Crooks BN; Fernandez CV
    J Pediatr; 2005 Jul; 147(1):106-8. PubMed ID: 16027706
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
    Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
    BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry.
    Polgreen LE; Bay L; Clarke LA; Guffon N; Jones SA; Muenzer J; Flores AL; Wilson K; Viskochil D
    Am J Med Genet A; 2022 Oct; 188(10):2941-2951. PubMed ID: 35869927
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience.
    Wiseman DH; Mercer J; Tylee K; Malaiya N; Bonney DK; Jones SA; Wraith JE; Wynn RF
    J Inherit Metab Dis; 2013 Mar; 36(2):263-70. PubMed ID: 22718273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. alpha-L-iduronidase therapy for mucopolysaccharidosis type I.
    Tolar J; Orchard PJ
    Biologics; 2008 Dec; 2(4):743-51. PubMed ID: 19707455
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome.
    Eisengart JB; Jarnes J; Ahmed A; Nestrasil I; Ziegler R; Delaney K; Shapiro E; Whitley C
    Mol Genet Metab Rep; 2017 Dec; 13():64-68. PubMed ID: 28983455
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.
    Pasqualim G; Baldo G; de Carvalho TG; Tavares AM; Giugliani R; Matte U
    PLoS One; 2015; 10(2):e0117271. PubMed ID: 25646802
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Enzyme-replacement therapy in mucopolysaccharidosis I.
    Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
    N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
    Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
    J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.